On May 23, 2017 Lytix Biopharma reported that the poster "LTX-315, an oncolytic peptide converts immunogenically ‘cold’ tumors to ‘hot’ in a majority of patients with advanced or metastatic tumours: results from an ongoing phase I study" will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2017 (ASCO) (Free ASCO Whitepaper) (Press release, Lytix Biopharma, MAY 23, 2017, View Source [SID1234519275]). The poster includes safety, efficacy and immune data on 28 patients treated with LTX-315 monotherapy in advanced/metastatic tumours. Schedule your 30 min Free 1stOncology Demo! Poster Session: Developmental therapeutics-immunotherapy, June 5th 8-11.30AM EST.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract number: 3085
The abstract can be found on: View Source